Peptide Market Trend: Glucagon’s Role in Diabetes Care Evolution
Abstract: Glucagon, a 29-amino acid peptide, is pivotal in diabetes care evolution, shifting from emergency hypoglycemia rescue to dual-hormone artificial pancreas systems. The peptide market, valued at $38.5B (2024), sees glucagon analogs (e.g., dasiglucagon) offering superior stability vs. native forms. Key brands (Baqsimi, Gvoke) compete on delivery (nasal vs. injectable) and shelf-life (24–36 months). Regulatory certifications (FDA, EMA) ensure purity (>98%) and bioactivity. Selecting high-quality glucagon requires verifying cold-chain logistics (2–8°C) and manufacturer GMP compliance. Industry trends show 8.2% CAGR growth, driven by automated insulin delivery integration and expanded indications for type 1 diabetes management.